Market revenue in 2023 | USD 157.0 million |
Market revenue in 2030 | USD 325.0 million |
Growth rate | 11% (CAGR from 2023 to 2030) |
Largest segment | Naltrexone |
Fastest growing segment | Naltrexone |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Buprenorphine, Naltrexone |
Key market players worldwide | Indivior PLC Ordinary Share, Collegium Pharmaceutical Inc, Alkermes PLC, Orexo AB, Titan Pharmaceuticals Inc, Omeros Corp, Camurus AB, Sun Pharmaceutical Industries |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to naltrexone and buprenorphine market will help companies and investors design strategic landscapes.
Naltrexone was the largest segment with a revenue share of 70% in 2023. Horizon Databook has segmented the France naltrexone and buprenorphine market based on buprenorphine, naltrexone covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the France naltrexone and buprenorphine market , including forecasts for subscribers. This country databook contains high-level insights into France naltrexone and buprenorphine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account